PT  - JOURNAL ARTICLE
AU  - MASAYUKI NAKASHIMA
AU  - MASATO TAKEUCHI
AU  - SHIRO TANAKA
AU  - KOJI KAWAKAMI
TI  - Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis
AID  - 10.21873/anticanres.14862
DP  - 2021 Feb 01
TA  - Anticancer Research
PG  - 1055--1062
VI  - 41
IP  - 2
4099  - http://ar.iiarjournals.org/content/41/2/1055.short
4100  - http://ar.iiarjournals.org/content/41/2/1055.full
SO  - Anticancer Res2021 Feb 01; 41
AB  - Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.